Equities analysts forecast that RedHill Biopharma Ltd (NASDAQ:RDHL) will announce earnings of ($0.47) per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for RedHill Biopharma’s earnings. The lowest EPS estimate is ($0.50) and the highest is ($0.45). RedHill Biopharma reported earnings of ($0.60) per share in the same quarter last year, which indicates a positive year over year growth rate of 21.7%. The company is scheduled to report its next quarterly earnings report on Tuesday, July 24th.
According to Zacks, analysts expect that RedHill Biopharma will report full-year earnings of ($1.77) per share for the current fiscal year, with EPS estimates ranging from ($1.83) to ($1.70). For the next year, analysts anticipate that the company will post earnings of ($1.30) per share, with EPS estimates ranging from ($1.70) to ($1.00). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow RedHill Biopharma.
RedHill Biopharma (NASDAQ:RDHL) last issued its quarterly earnings data on Tuesday, May 8th. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.50). RedHill Biopharma had a negative net margin of 726.64% and a negative return on equity of 114.27%. The firm had revenue of $2.45 million for the quarter, compared to the consensus estimate of $2.14 million.
A number of research analysts have recently issued reports on RDHL shares. Zacks Investment Research raised shares of RedHill Biopharma from a “hold” rating to a “buy” rating and set a $6.75 price objective on the stock in a research report on Saturday, May 12th. ValuEngine downgraded shares of RedHill Biopharma from a “sell” rating to a “strong sell” rating in a research report on Tuesday, May 8th. Finally, HC Wainwright set a $36.00 price objective on shares of RedHill Biopharma and gave the stock a “buy” rating in a research report on Wednesday, May 9th. Two equities research analysts have rated the stock with a sell rating and six have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $19.95.
Shares of RedHill Biopharma stock traded down $0.19 on Thursday, reaching $7.00. The stock had a trading volume of 53,804 shares, compared to its average volume of 96,426. RedHill Biopharma has a 1 year low of $4.30 and a 1 year high of $11.25. The company has a market cap of $152.53 million, a P/E ratio of -2.69 and a beta of 0.80.
A number of hedge funds have recently added to or reduced their stakes in the stock. 683 Capital Management LLC acquired a new stake in RedHill Biopharma in the 4th quarter worth approximately $5,136,000. Creative Planning acquired a new stake in RedHill Biopharma in the 4th quarter worth approximately $722,000. Virtu Financial LLC acquired a new stake in RedHill Biopharma in the 4th quarter worth approximately $312,000. Meitav Dash Investments Ltd. acquired a new stake in RedHill Biopharma in the 4th quarter worth approximately $244,000. Finally, Citadel Advisors LLC acquired a new stake in RedHill Biopharma in the 4th quarter worth approximately $170,000. Institutional investors own 20.03% of the company’s stock.
RedHill Biopharma Company Profile
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on the development and commercialization of late clinical-stage, proprietary, and in-licensed/acquired drugs for the treatment of gastrointestinal and inflammatory diseases, and cancer. The company commercializes three gastrointestinal products in the United States, such as Donnatal, a prescription oral adjunctive drug used in the treatment of irritable bowel syndrome (IBS), and acute enterocolitis and duodenal ulcers; EnteraGam, a prescription medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools; and Esomeprazole Strontium Delayed-Release Capsules 49.3 mg, a prescription proton pump inhibitor drug product indicated for adults for the treatment of GERD, risk reduction of NSAID-associated gastric ulcer, Helicobacter pylori eradication to reduce the risk of duodenal ulcer recurrence, and for pathological hypersecretory conditions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.